Aether Industries (AETHER) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
15 May, 2026Executive summary
FY26 revenue grew 38% YoY to ₹11,601 million, with PAT up 39% to ₹2,195 million, driven by strong pricing, CEM, CRAMS, and large scale manufacturing expansion.
19 new marquee clients added and 50+ customer audits completed, reinforcing global relationships and operational excellence.
Significant R&D progress with interim expansion completed and a new world-class facility on track for FY28 commissioning.
Commercial production at Site 3 began in late February; Site 5 phase one solvent trials started, targeting commercial production in Q1 FY27.
Appointment of Mr. Guenter Stevens as Senior Managerial Personnel for business development in Europe, effective June 1, 2026.
Financial highlights
FY26 consolidated revenue: ₹11,601 million (up 38% YoY); EBITDA: ₹3,547 million (up 53% YoY); PAT: ₹2,195 million (up 39% YoY).
Q4 FY26 revenue: ₹3,051 million, EBITDA: ₹814 million, PAT: ₹540 million; Q4 impacted by a ₹70 million inventory loss from a warehouse fire.
EBITDA margin improved to 31% in FY26 (from 28%); PAT margin at 19% (from 18%).
Cash flow from operations increased to ₹1,424 million (from ₹1,000 million YoY).
EPS (consolidated, basic) for FY26 was ₹16.55, up from ₹11.95 in FY25.
Outlook and guidance
Site 3 ramp-up and Site 5 commercial production expected in Q1 FY27, supporting future growth.
Major growth drivers for FY27: ramp-up of Site 3+, Site 4, and commercialization of Site 5 (phase I).
Targeting 70% of revenue from CRAMS and CM by FY30, with 30% from large scale manufacturing.
Working capital days expected to reduce to 160 by FY27, with a long-term goal of 150 days.
CapEx for FY27 projected at ₹3,000–3,500 million, mainly for Site 5 and new R&D site.
Latest events from Aether Industries
- Revenue and profit surged year-over-year, driven by strong demand and site expansions.AETHER
Q3 25/263 Feb 2026 - Q1 FY25 delivered strong growth, margin recovery, and major capital raise approval.AETHER
Q1 24/252 Feb 2026 - Q1 FY26 revenue up 35% Y/Y, EBITDA up 94%, with major expansions and exclusive Milliken deal.AETHER
Q1 25/2619 Dec 2025 - Q3 FY25 saw strong growth, margin gains, and major site and customer expansions.AETHER
Q3 24/2519 Dec 2025 - Q2 and H1 FY25 delivered strong growth, robust margins, and ongoing expansion initiatives.AETHER
Q2 24/2519 Dec 2025 - Q2 FY26 delivered 38% revenue and 70% EBITDA growth, with CEM/CRAMS over 50% of sales.AETHER
Q2 25/2619 Dec 2025 - Strong FY25 revenue and profit growth, margin expansion, and robust recovery post-fire incident.AETHER
Q4 24/2519 Dec 2025